Affymetrix Technology Powers First Genomic Tumor Grading Test For Breast Cancer

[News]

Affymetrix Inc. (Nasdaq: AFFX) announced that its technology powers the Ipsogen MapQuant Dx? Genomic Grade, the first genomic test designed to provide a more precise measurement of tumor grade than previous techniques. Ipsogen, a leading French molecular diagnostic company, launched the test, which resulted from the Powered by Affymetrix? agreement signed in August 2007.

More... (http://www.medicalnewstoday.com/articles/109547.php)